Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
11/29/20 11:40 AM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Nov 23 2020
Summary ToggleAdverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
- Nov 14 2020
Summary ToggleAdverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
- Nov 5 2020
Summary ToggleAdverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results
- Oct 20 2020
Summary ToggleAdverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual